STAT+: A scientist-turned-biotech executive is notching some wins, and enjoying it — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Greg Verdine, a scientist-turned-biotech entrepreneur, is having what the source describes as "a very good year" across two simultaneous ventures.
- Parabilis Medicines went public in June in one of the biotech industry's largest IPOs in recent years, according to the source.
- LifeMine raised $263 million in a round announced Thursday, money Verdine said will advance a drug aimed at making organ transplants more viable.
- Verdine believes the same LifeMine candidate could also potentially help people with autoimmune conditions, broadening its potential beyond transplant recipients.
- Verdine credited science he tried to propel forward nearly 15 years ago with potentially changing the pancreatic cancer treatment landscape.
Why it matters: Verdine is running two high-profile biotech bets at once — Parabilis, now public via one of the sector's largest recent IPOs, and LifeMine, freshly capitalized with $263 million to chase a transplant-enabling drug that Verdine also expects to apply to autoimmune disease. Patients awaiting organ transplants and those with autoimmune conditions are the named downstream stakeholders whose treatment options ride on whether Verdine's pipeline delivers.
Ask SkimNews
